BioLineRx Annouces Expansion of 2016 Collaboration with Merck&Co. in Immuno-Oncology in pancreatic cancer
Shots:
- Under the expansion collaboration- new arm of assessment is added assessing BL-8040- Keytruda and chemo in 2L patient in COMBAT/KEYNOTE-202 study
- Results of Ph2a COMBAT study is expected in H2'18 as planned
- This study is assessing combination of BL-8040 & Keytruda in metastatic 1L+ patients
Ref: Biolinerx | Image: Merck
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
